

# Pre and Post Semaglutide Era: A Comparative Study of Bariatric Surgery Outcomes



SRI AUROBINDO  
UNIVERSITY  
VISION WITH ACTION



**Dr. Winnie Mathur**

Bariatric Program Director- Research Associate

Virtual Bariatric University Program Coordinator

**Mohak** Bariatrics and Robotics, Indore

XXVII Ifso World Congress



Melbourne 2024

# GLP-1 Analog (Glucagon-Like Peptide-1 Analog)

GLP-1 is a hormone that plays a crucial role in regulating glucose metabolism and appetite.

GLP-1 analogs are synthetic compounds that mimic the action of GLP-1.

They are used in the treatment of obesity and type 2 diabetes because they can reduce appetite, slow down gastric emptying, and promote a feeling of fullness.

Common GLP-1 analogs include liraglutide and semaglutide.



# Aim

To compare the outcomes of bariatric surgery in patients who received semaglutide as part of a preoperative program with those who did not.

# Methodology


- Out of 22, 10 patients received semaglutide along with a very low-calorie diet (VLCD) program for 15 days at 7mg and an additional 15 days at 14mg before surgery. **(Group-I)**
- The remaining 12 patients followed a VLCD without semaglutide. **(Group-II)**
- Postoperative assessments were conducted at 1 month before surgery and 3 and 6 months after surgery.

## Demographic Characteristics of the Patients

Demographic Variables	Group-I (n=10)	Group-II (n=12)	p-value
Age, yr. (95%CI)	42.1±12.3 (38.6-45.2)	40.2±12.6 (36.8-43.6)	0.454
Height, cm (95%CI)	166.3±9.7 (163.6-169.0)	166.6±13.1 (163.1-170.2)	0.888
Weight, kg (95%CI)	266.8±18.2 (104.7-114.8)	206±28.9 (105.3-121.0)	0.172
BMI, kg/m <sup>2</sup>	96.5±4.3 (38.3-40.6)	74.8±9.8 (37.7-42.6)	0.109
T2DN, n(%)	20%	10%	0.553
OSA, (%)	83%	78%	0.978
HTN, n(%)	48%	35%	0.381

# Results

## Weight-loss outcome



# Conclusion

- The addition of semaglutide in the preoperative regimen for bariatric surgery appears significant outcomes in terms of weight loss and postoperative recovery.
- Although semaglutide patients experienced slightly more gastrointestinal side effects, the benefits of a shorter hospital stay, and greater weight loss may make this approach a promising option for morbid obese individuals.
- Further research and long-term follow-up are necessary to determine the lasting impact of semaglutide on bariatric surgery outcomes.



# MOHAK TEAM THANK YOU

We offer various treatment modalities for obesity. The operation is determined by the profile of the patient and guided by findings from analysis of the data from our prospectively maintained database

XXVII Ifso World Congress



Melbourne 2024